Tag Archives: NA

MannKind Q1 ’17 Earnings Update

MannKind held its Q1 2017 earnings call and provided updates on commercial and clinical activities for Afrezza.

This content is for Read Less members only.
Register

Already a member? Log in here

Lexicon announces additional Ph3 sotagliflozin results in T1DM

Lexicon has announced additional positive data from the Ph3 inTandem1 study. Of note, a slight increase in DKA was seen in the sotagliflozin groups during the extension period with 6 cases (2.5%) on 200mg and 3 cases (1.3%) for 400mg compared to 1 patient (0.4%) on placebo.

This content is for Read Less members only.
Register

Already a member? Log in here

Mylan Q1 2017 Earnings Update

On May 10th, Mylan hosted its Q1 2017 earnings call and briefly discussed its insulin glargine development program.

This content is for Read Less members only.
Register

Already a member? Log in here

Mannkind and One Drop enter collaboration for better diabetes outcomes

MannKind Corporation and One Drop are entering into a collaborative agreement that would extend One Drop’s subscription service and digital health platform through the addition of Afrezza as a rapid-acting insulin offering integrated in-app with Bluetooth technology.

This content is for Read Less members only.
Register

Already a member? Log in here

Lexicon Q1 ’17 Earnings Update

Lexicon hosted its Q1 earnings call and provided updates to their T1DM and T2DM diabetes development programs for sotagliflozin and LX2761.

This content is for Read Less members only.
Register

Already a member? Log in here

Lilly Q1 ’17 Earnings Update

Lilly hosted its Q1 ’17 earnings call and provided an update to its diabetes portfolio including pipeline and LCM activities.

This content is for Read Less members only.
Register

Already a member? Log in here

Lilly Initiates Ph1 for New OAD

A Lilly sponsored Ph1 ClinicaTrials.gov record has been observed for LY3325656. According to the record, the compound is dosed orally and is being compared to liraglutide and in combination with sitagliptin. MOA for LY3325656 remains to be determined.

This content is for Read Less members only.
Register

Already a member? Log in here

J&J Q1 ’17 Earnings Update

J&J presented its Q1 ’17 earnings results and provided a brief update to its diabetes business including drugs and devices. Of note, J&J is hosting its Pharmaceutical Business Review on May 17.

This content is for Read Less members only.
Register

Already a member? Log in here

Invokana CKD Outcomes Trial (CREDENCE) Primary Completion Date Delayed

The ClincalTrials.gov record for the CREDENCE trial has been updated to reflect a later primary completion date. The estimated primary completion date has been pushed back from February 11, 2019 to June 28, 2019, which may be due to trial recruitment.

This content is for Read Less members only.
Register

Already a member? Log in here

Merck’s Januvia Receives CRL from FDA for TECOS

Merck has announced it received a complete response letter (CRL) regarding its submission of data from the TECOS cardiovascular outcomes trial for Januvia (sitagliptin). The company has not disclosed the reason for the CRL, but said it is working with FDA to discuss next steps.

This content is for Read Less members only.
Register

Already a member? Log in here